Last reviewed · How we verify
Oral PF-06821497 (oral-pf-06821497)
At a glance
| Generic name | oral-pf-06821497 |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Vessel puncture site bruise
- Nail avulsion
- Neck pain
- Disturbance in attention
- Eyelid pain
- abdominal discomfort
- Abdominal pain
- Constipation
- Nausea
- Vessel puncture site pain
- Fall
Key clinical trials
- A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. (PHASE3)
- A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (PHASE1)
- This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. (PHASE3)
- A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants. (PHASE1)
- A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral PF-06821497 CI brief — competitive landscape report
- Oral PF-06821497 updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI